For Immediate Release
Chicago, IL – April 7, 2010 – Today Zacks.com features the Top 5 Healthcare Funds; Delaware Healthcare A (DLHAX), Kinetics Medical No Load (MEDRX), Manning & Napier Life Sciences (EXLSX), Rydex Biotechnology (RYOIX) and Franklin Biotechnology Discovery A (FBDIX). These Healthcare funds are given our highest rating; Zacks #1 Ranked Strong Buys. That means we expect these funds to outperform their peers in the future.
Zacks.com provides exclusive ratings on over 18,000 funds in 42 different categories. To learn more about Zacks Mutual Fund Rank, click here. http://at.zacks.com/?id=6760
Zacks #1 Ranked Healthcare Funds
Delaware Healthcare A (DLHAX) seeks long-term capital growth. It invests the majority of its assets in equity securities of healthcare companies. It invests in domestic and foreign companies with a wide range of market capitalizations. It may also purchase securities issued by emerging market companies. The health fund returned 83.84% over the last one year period.
The Fund Manager is Liu-Er Chen and he has managed this health fund since 2007.
Kinetics Medical No Load (MEDRX) invests at least 80% of its assets in domestic and foreign healthcare companies engaged in medical research. It focuses on companies whose primary operations include drug discovery and cancer research. It primarily purchases stocks convertible securities, warrants and ADRs. Up to 20% of its assets may be invested in unrated debt securities as well as those rated below investment grade. It is a no load fund.
The health fund returned 42.32% in the last one year and has a five year annualized return of 6.76%.
Manning & Napier Life Sciences (EXLSX) seeks capital appreciation by investing heavily in securities of companies from the life sciences sector. Domestic and foreign equity, ADRs and U.S. dollar denominated foreign securities make up the majority of its assets. The health fund has a five year annualized return of 6.69%.
The health fund has a minimum initial investment of $2,000 and an expense ratio of 1.12% compared to a category average of 1.98%.
Rydex Biotechnology (RYOIX) invests the majority of its assets in equity securities and derivatives issued by domestic biotechnology companies. It is non-diversified and seeks long-term capital growth. The health fund returned 41.55% in the last one year period and has a three year annualized return of 6.55%.
Michael J. Dellapa is the fund manager and he has managed this health fund since 2006.
Franklin Biotechnology Discovery A (FBDIX) seeks long-term capital growth. It invests the majority of its assets in biotechnology and discovery research companies located in the U.S. or Europe as well as other countries. It may also utilize a smaller portion of its assets to acquire debt securities issued from these countries. The health fund returned 24.36% over the last one year period.
This healthcare fund has an expense ratio of 1.32% compared to a category average of 1.98%.
To view the Zacks Rank and past performance of all Healthcare Funds then click here.
About Zacks Mutual Fund Rank
The Zacks Mutual Fund Rank is a quantitative ratings system created by Len Zacks, a PHD in mathematics from MIT. The goal of the rank is simple; goal to help investors find the best mutual funds to beat the market.
To discover how the Zacks mutual fund rank works and to receive daily notifications on our fund rankings, click here:
http://at.zacks.com/?id=5855
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Len Zacks. The company continually processes stock reports issued by 3,000 analysts from 150 brokerage firms. It monitors more than 200,000 earnings estimates, looking for changes.
Then when changes are discovered, they’re applied to help assign more than 4,400 stocks into five Zacks Rank categories: #1 Strong Buy, #2 Buy, #3 Hold, #4 Sell, and #5 Strong Sell. This proprietary stock picking system; the Zacks Rank, continues to outperform the market by nearly a 3 to 1 margin.
To discover all Zacks has to offer investors like yourself, then go to our home page at www.zacks.com
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Contact: Jim Giaquinto
Company: Zacks.com
Phone: 312-265-9149
Email: pr@zacks.com
Visit: www.zacks.com
